OrbiMed Advisors
UnclaimedAt a Glance
- Check Size
- $1M – $75M
- Stage
- Series A, Series B+
- AUM
- $15B
- Sectors
- Biotech, Digital Health
- Founded
- 1989
- HQ
- New York, NY
About OrbiMed Advisors
OrbiMed Advisors is a venture capital firm based in New York, NY founded in 1989. The firm focuses on Series A, Series B+ investments across sectors including Biotech, Digital Health. The firm manages $15B in assets under management. Notable portfolio companies include Foundation Medicine, 10x Genomics, Veracyte, Moderna, BioNTech, Guardant Health and Exact Sciences. Healthcare-focused investment platform spanning all stages from seed through IPO in biotech, pharmaceuticals, and digital health.
Investment Thesis
“Healthcare-focused investment platform spanning all stages from seed through IPO in biotech, pharmaceuticals, and digital health.”
Sector Focus
Investment Stage
Notable Portfolio Companies
SEC Fund Filings
- Vehicles filed, last 24 months
- 4
- Latest filing
OrbiMed Advisors filed a Form D for 4 fund vehicles between Sep 26, 2024 and Sep 25, 2026.
| Fund vehicle | Source |
|---|---|
| OrbiMed Asia Partners VI, L.P. | SEC Form D, filed |
| OrbiMed Private Investments X, LP | SEC Form D, filed |
| OrbiMed RCO V Offshore Feeder, LP | SEC Form D, filed |
| OrbiMed Royalty & Credit Opportunities V, LP | SEC Form D, filed |
A Form D is the notice a fund files with the SEC when it raises money in a private offering. Feeder funds, parallel funds and SPVs each file their own, so the count measures filing activity, not the number of flagship funds.
Source: SEC EDGAR Form D filings for pooled investment funds, original filings only (amendments excluded). Our filing data starts Jul 1, 2024. Vehicles are matched to OrbiMed Advisors by fund name and checked against the sponsor address and named principals on each filing; offering amounts are not shown. Each “SEC Form D” link opens an EDGAR full-text search for that vehicle’s exact name, where the filing itself is listed. See every new fund filing on the Form D Radar.
Team (7)
Carter Neild
Managing Partner, OrbiMed Advisors
David Bonita
General Partner, OrbiMed Advisors
Geoffrey C. Hsu
General Partner, OrbiMed Advisors
Matthew Rizzo
General Partner, OrbiMed Advisors
Peter Thompson
General Partner, OrbiMed Advisors
Scotland Stevens
General Partner, OrbiMed Advisors
Sven H. Borho
Managing Partner, OrbiMed Advisors
Frequently Asked Questions
What stage does OrbiMed Advisors invest at?
OrbiMed Advisors primarily invests at the Series A, Series B+ stages. This means they focus on companies that are scaling their go-to-market after proving product-market fit.
Where is OrbiMed Advisors located?
OrbiMed Advisors is headquartered in New York, NY. Many of their portfolio companies are also based in this region, though they invest across geographies.
What sectors does OrbiMed Advisors focus on?
OrbiMed Advisors focuses on investments in Biotech, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.
What is OrbiMed Advisors's typical check size?
OrbiMed Advisors's typical investment check size ranges from $1M to $75M. Actual amounts may vary based on the stage, sector, and specific opportunity.
How much does OrbiMed Advisors have under management?
OrbiMed Advisors manages approximately $15B in assets under management (AUM) across their funds.
Similar Firms
Fund Operations Resources
Running a fund like OrbiMed Advisors? Independent guides to the software and processes emerging managers use to operate.
Best Fund Administration Software
Independent breakdown of fund administration platforms by fund size.
LP Reporting Software
Tools for capital account statements and investor updates.
Portfolio Monitoring Tools
How GPs track company performance across the portfolio.
VC CRM Software
Deal-flow and relationship management for investors.
Related tools and reading
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.